JUMPCAN

AASTOCKS · Feb 3 at 09:42 AM

AKESO grants commercialization rights for Yixinning, receiving a licensing fee of 80 million RMB

Wallstreetcn · Jan 27 at 04:41 AM

With only six months left until July 1, 2026, the implementation of Article 75 of the National Medical Products Administration's "Special Regulations on the Registration of Traditional Chinese Medicine" is entering its final window period. This regulation, referred to in the industry as the "death clause" for proprietary Chinese medicines, clearly states that after three years of implementation starting from July 1, 2023, the contraindications in the instructions will be prohibited

Zhitong · Sep 16, 2025 at 03:35 AM

JUMPCAN's subsidiary has obtained the drug registration certificate for lidocaine gel patches

Zhitong · Sep 7, 2025 at 08:01 PM

Zhitong A-share lock-up release overview | September 8

Zhitong · Sep 3, 2025 at 03:26 AM

Cao Fei intends to acquire JUMPCAN, and the supervision situation in the second quarter has been good

Zhitong · Aug 22, 2025 at 07:57 AM

JUMPCAN released its performance for the first half of the year, with a net profit attributable to the parent company of 724 million yuan, a year-on-year decrease of 45.87%